A short investor post points to high cardiovascular risk among the diabetics studied and calls retatrutide's heart risk uncertain. The full take is cut off.
Recap by typeshit. Post by Bioinvestor24 on X.
A short Facebook share with no context on who used the peptides, where it happened or what followed.
Benzinga notes a 1.89% after-hours gain for Lilly stock, with Novo Nordisk also tagged. No further detail on what drove the move.
Mikhail Varshavski tells Fox News why protein matters, especially for GLP-1 users. He has a paid partnership with Quest Nutrition.
2:07:50
A live Q&A session covering GLP-1 drugs including Zepbound, Wegovy and Foundayo, with the host taking questions from viewers.
A Cary-based company pulled its GLP-1 injections following attention from the FDA. The Business Journals has the details on the recall.
Amgen pointed to encouraging interim MariTide data and says the drug is moving quickly toward late-stage testing ahead of its Q3 earnings.
Loading…